INDV 6-K
Indivior Pharmaceuticals, Inc. (INDV)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of November 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☒ Form 40-F ☐
EXHIBIT INDEX
| Exhibit No. | Description of Exhibit |
|---|---|
| 99.1 | Announcement sent<br>to the London Stock Exchange on November 22, 2024, titled<br>“Indivior to Participate in Upcoming Investor<br>Event”. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Indivior PLC | |
|---|---|
| Date: November 22, 2024 | /s/<br>Kathryn Hudson |
| Name:<br>Kathryn Hudson | |
| Title:<br>Company Secretary |
a2313n-2
Exhibit 99.1
Indivior To Participate in Upcoming Investor Event
Slough, UK, and Richmond, VA, November 22, 2024 – Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor event:
●
Piper Sandler 36th Annual Healthcare Conference – New York City, NY
Mark Crossley, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Tuesday, December 3rd. Mark Crossley will also participate in a fireside discussion on Tuesday, December 3rd at 10:00 a.m. US ET. Interested investors should contact their Piper Sandler representative to schedule a meeting. The fireside chat will be publicly available and can be viewed using the following weblink:
https://event.webcasts.com/starthere.jsp?ei=1697247&tp_key=c34d7b2697
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-402-7123 or [email protected]
Tim Owens
Director, Investor Relations
Tel: 804-263-3978 or [email protected]